Find a Clinical Trial
The clinical trials at Gundersen offer the same cutting-edge treatments as those at other top medical research hospitals – and often much sooner than they’re available to everyone.
Showing 10 of 89 trials
20324
Study to Learn More About the Safety and Effectiveness of the Drug VITRAKVI During Routine Use in Patients With TRK Fusion Cancer Which is Locally Advanced or Spread From the Place Where it Started to Other Places in the Body
Child (birth - 17)
Adult (18-64)
Older adult (65+)
EA2183
Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body
Adult (18-64)
Older adult (65+)
AZA-MDS-006
Connect® Myeloid Disease Registry
Adult (18-64)
Older adult (65+)
A231901CD
Improving Patient-Centered Communication in Breast Cancer Through Patient and Provider Interventions
Child (birth - 17)
Adult (18-64)
Older adult (65+)
EAA181
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Adult (18-64)
Older adult (65+)
NCI-2020-03472
Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial
Adult (18-64)
Older adult (65+)
NCI-2020-08331
Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma
Adult (18-64)
Older adult (65+)
S2213
Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis
Adult (18-64)
Older adult (65+)
NCI-2022-07265
Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial)
Adult (18-64)
Older adult (65+)
A052101
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
Adult (18-64)
Older adult (65+)